Japanese Foundation for Cancer Research Report issue

Foundation Phase 1 Phase 3

Organization Overview

First Clinical Trial
2007
NCT00561275
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cancer Institute of Japanese Foundation for Cancer Research | Japanese Foundation for Cancer Research

Active Ingredients

Drugs in Phase 3 Trials (3)

atezolizumab (Tecentriq) (1 trial)

bevacizumab (avastin) (1 trial)

paclitaxel (taxol) (1 trial)

Drugs in Phase 1 Trials (1)

ly6k, vegfr1, vegfr2 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Esophageal Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4